fbpx

U.S. Anti-Doping Agency (USADA)

Click here to log in to the
Athlete Connect application

Click here to log in to
Athlete Express

USADA logo with registered symbol.

Global DRO logo in whiteSearch Medications & Ingredients

Search
Search
Close this search box.

close up of group of cyclists wheels and feetUSADA announced today that Sidney Andrew, of Boulder, Colo., an athlete in the sport of cycling, has accepted a 12-month suspension for an anti-doping rule violation.

Andrew, 26, tested positive for 5-methylhexan-2-amine as the result of an in-competition drug test conducted at the Joe Martin Stage Race on May 21, 2022. 5-methylhexan-2-amine (also known as 1,4-dimethylpentylamine (DMPA) or 2-amino-5-methylhexane) is a Specified Substance in the category of Stimulants and is prohibited in competition under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policy, and the International Cycling Union Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

Following an investigation into the circumstances of her case, USADA determined that Andrew’s positive test was caused by her use of a dietary supplement. Detailed analysis conducted on the supplement by the WADA-accredited laboratory in Salt Lake City, Utah, confirmed that the supplement contained 5-methylhexan-2-amine. Although 5-methylhexan-2-amine was not listed on the Supplement Facts label, another prohibited Stimulant, 1,3-dimethylamylamine (DMAA, methylhexanamine), was listed on the label. The supplement has been added to the USADA High Risk List.

5-methylhexan-2-amine is very similar to DMAA and 1,3-dimethylbutylamine (DMBA). All have been discovered in pre-workout supplements and the U.S. Food and Drug Administration (FDA) has put out specific warnings on DMAA and DMBA in the past.

Athletes and other sport stakeholders are reminded that, unlike medications, dietary supplements sold in the U.S. do not receive any pre-market safety or efficacy reviews by government authorities. Thus, an increased level of due diligence is necessary to challenge the reasons for use and understand the risks of a positive anti-doping test and/or an adverse health event.

Andrew’s 12-month period of ineligibility began on June 21, 2022, the date her provisional suspension was imposed. In addition, Andrew has been disqualified from competitive results obtained on and subsequent to May 21, 2022, the date her positive sample was collected, including forfeiture of any medals, points and prizes.

In an effort to aid athletes, as well as support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to file and update athlete Whereabouts, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.

In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and distributes a multitude of educational materials, such as a supplement guide, a nutrition guide, a clean sport handbook, and periodic alerts and advisories.

USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by text at 87232 (“USADA”), by email at playclean@USADA.org, by phone at 1-877-Play Clean (1-877-752-9253) or by mail.

USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.


For more information or media inquiries, click here.